M. tuberculosis

We have developed multiple compounds showing in vitro activity with collaborators. Our most advanced candidate is a third generation DprE1 inhibitor with potent in vitro and in vivo efficacy. We are keen to pursue this as a novel, long acting agent. A second compound with promising in vitro activity is currently being evaluated.

Lane TR, Urbina F, Rank L, Gerlach J, Riabova O, Lepioshkin A, Kazakova E, Vocat A, Tkachenko V, Cole S, Makarov V, Ekins S. Machine Learning Models for Mycobacterium tuberculosisIn Vitro Activity: Prediction and Target Visualization. Mol Pharm. 2022 Feb 7;19(2):674-689. doi: 10.1021/acs.molpharmaceut.1c00791. Epub 2021 Dec 29.PMID: 34964633